Polycythaemia vera+4
RecruitingStudy on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms
Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms
- Disease:Polycythaemia veraEssential thrombocythaemia+3
- Substances:Acetylsalicylic AcidApixaban+1
France- Participants:18–64 years · 65+ years
- Substances:Acetylsalicylic Acid
- Sponsor:Centre Hospitalier Regional Et Universitaire De Brest







